Toxicity, Metabolism And Excretion Of [60]Fullerene In Rats

Najla Gharbi,¹ Monique Pressac,² Michelle Hadchouel,³ Henri Szwarc,⁴ Rene Victor Bensasson ⁵ And Fathi Moussa ¹*

¹ Faculté De Pharmacie, Université Paris Xi, Rue J-B Clement-F92296 Chatenay-Malabry, France
² Faculté De Pharmacie, Université Paris V, Rue De L’observatoire-F75006, Paris, France
³ Inserm, Unité 347, Chu Kremelin-Bicêtre, Rue Du Gal Leclerc-F94265 Kremelin-Bicêtre, France
⁴ UMR 8000 Du Cnrs, Batiment 490, Université Paris Sud, 91405 Orsay, France
⁵ ESA 8041 CNRS, Muséum National D’histoire Naturelle, 63 Rue Buffon-F75005 Paris

Over the last decade, it has been shown that some fullerene derivatives exhibit considerable biological activity; however, only few additional studies concerning fullerene toxicity have been performed. Most of these studies suggest that C₆₀ accumulates in the liver and remains apparently unchanged with no acute toxic effects in general. Therefore, use of C₆₀ derivatives that could be cleaved back to the parent C₆₀ in vivo would likely lead to long-term fullerene accumulation (1), which is a negative factor for potential biomedical applications.

We report here the in vivo behavior and potential metabolism of C₆₀ in rats, after intraperitoneal injection of a single large dose (0.5 g/kg) of an aqueous suspension of micronized C₆₀. Our results show that: i) most of the C₆₀ crystals (< 2 µm) accumulate in the liver and spleen within 2 to 4 days as revealed by light and electronic microscopy as well as by HPLC determination; ii) there is no acute toxicity; iii) C₆₀ reacts with vitamin A and its ester forms in rat livers as previously observed in mouse livers (2); iv) C₆₀ is slowly but significantly eliminated (up to 7 mg per week) through the bile ducts as demonstrated by HPLC analysis of feces extracts. The mechanism of elimination is now under investigation in our laboratory.;

Acknowledgement. This work was performed under European contract "Evaluation of the biological properties of fullerenes and new fullerene derivatives" (ERB FMRX-CT98-0192)

* Corresponding author: Tel. 01 46 83 54 72, Fax. 01 46 83 53 06, Email: fathi.moussa@cep.u-psud.f